Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat OLE in Hypertension
NCT05459688Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of baxdrostat in hypertension (HTN), sponsored by AstraZeneca. Started Apr 2022; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05459688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459688.